Q&A: Re­silience boss Rahul Singhvi talks $2B US bio­man­u­fac­tur­ing ini­tia­tive and post Se­ries D deals

When the Biden ad­min­is­tra­tion an­nounced last week, through an ex­ec­u­tive or­der, that it is in­vest­ing $2 bil­lion in­to do­mes­tic ef­forts to in­crease biotech­nol­o­gy and bio­man­u­fac­tur­ing ef­forts, a lot of ears perked up in the wider man­u­fac­tur­ing world. Fund­ing is go­ing to­wards man­u­fac­tur­ing in­fra­struc­ture, train­ing, R&D and se­cu­ri­ty mea­sures, among oth­ers, some­thing that do­mes­tic man­u­fac­tur­ers are bull­ish about.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER